Clinical Trial

ESCC Molecular Subtypes Based on Multidimensional Features of p53 and Their Clinical Significance

Completed
View on ClinicalTrials.gov →
Summary
Collect 300 esophageal cancer tissue specimens, including cancer tissue and serum, from a biological sample bank. Collect clinical information on esophageal cancer, including gender, age, time of diagnosis, time of death, treatment information, TNM staging, tumor size, location, etc. DNA sequencing was performed on 300 collected esophageal cancer samples, divided into mutant and wild-type types. Perform immunohistochemistry on tissue slices and observe the expression of P53 mutant protein. ELISA was used to study the expression of serum anti-P53 autoantibodies. Process these data and use them to classify subtypes of esophageal cancer. Associate each subtype with clinical information, analyze the characteristics of each subtype, such as the multidimensional features of P53 and treatment correlation analysis, and the correlation between P53 multidimensional features and survival.
Trial Details
NCT Number NCT07722819
Lead Sponsor Ling Zhiqiang
Conditions P53 Mutation in Esophageal Cancer
Enrollment 300 participants
Start Date 2026-04-21
Primary Completion 2026-07-13 (estimated)
Study Completion 2026-07-13 (estimated)
Updated on ClinicalTrials.gov 2026-07-23